NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/12/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization18.73 mln
Float26.96 mln
Earnings Date08/17/2026
Piotroski F-Score
6
/ 9
Solid
Relative Strength
94
/ 100
Top performer
Debt / Equity
0.01
Debt-free
ROE
-69.00
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Citius Pharmaceuticals is a New Jersey-based company founded in 2007 that develops and sells medical treatments for serious conditions. Its flagship product, LYMPHIR, has received FDA approval as a targeted therapy for a type of skin cancer called cutaneous T-cell lymphoma. The company also has several treatments in late-stage development, including solutions for catheter-related bloodstream infections, hemorrhoid relief, and a stem cell therapy for acute respiratory distress syndrome.
